Abstract: A hybrid feeding device for automatically adjusting a co-firing amount of decaying garbage. The device comprises a mechanical grate furnace, a hybrid garbage conveying device, a raw garbage feeding device, a decaying garbage feeding device, a hybrid garbage crushing device, and a control center. The raw garbage feeding device, the decaying garbage feeding device, and the hybrid garbage conveying device are all connected to the control center. The decaying garbage feeding device is used for transporting decaying garbage to the raw garbage feeding device. The raw garbage feeding device is positioned between the decaying garbage feeding device and the hybrid garbage conveying device. The hybrid garbage crushing device is used for crushing garbage and inputting the garbage to the mechanical grate furnace. The mechanical grate furnace is internally provided with a plurality of temperature sensors, and the plurality of temperature sensors are connected to the control center.

Abstract: Disclosed herein are methods for treating a cancer in an individual, including administration of an R-spondin protein, for example one or more of R-spondin1, R-spondin2, R-spondin3, R-spondin4, and combinations thereof. Further disclosed are methods of treating an individual having a cancer, the method including determining an R-spondin level in the individual, and administering a treatment to the individual.

Abstract: An industrially scalable microcapsule, fiber or film forming process and formulations suitable for use in conventional spray drying systems are provided. The one-step spray drying process utilizes formulations of a first ionic polymer, a second ionic polymer with an isoelectric point (pI2) or acid dissociation constant (pKa2) that is greater than the isoelectric point (pI1) or acid dissociation constant (pKa1) of the first ionic polymer and a volatile base or volatile acid. Volatilization of the volatile base or acid of the spray formulation changes the pH of the solution and changes the charge of the second ionic polymer initiating electrostatic interactions with the first ionic polymer through complex coacervation. Microcapsules formed by the complex coacervation process can stabilize bioactive components as well as control the release of the bioactive components for a variety of applications.

Abstract: An industrially scalable microcapsule, fiber or film forming process and formulations suitable for use in conventional spray drying systems are provided. The one-step spray drying process utilizes formulations of a first ionic polymer, a second ionic polymer with an isoelectric point (pI2) or acid dissociation constant (pKa2) that is greater than the isoelectric point (pI1) or acid dissociation constant (pKa1) of the first ionic polymer and a volatile base or volatile acid. Volatilization of the volatile base or acid of the spray formulation changes the pH of the solution and changes the charge of the second ionic polymer initiating electrostatic interactions with the first ionic polymer through complex coacervation. Microcapsules formed by the complex coacervation process can stabilize bioactive components as well as control the release of the bioactive components for a variety of applications.

Abstract: The present invention relates to a fluoroallylamine derivative and use thereof. In particular, the present invention relates to a compound as shown in Formula I, a prodrug, an isomer, an isotope-labeled compound, a solvate or a pharmaceutically acceptable salt thereof, which has VAP-1/SSAO inhibitory activity, and can be used for treating a disease associated with VAP-1/SSAO overactivity.

Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.

Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.

Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.

Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.

Abstract: This invention provides novel arylindenopyridines of the formula: and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing Adensine A2a receptors or reducing PDE activity in appropriate cells. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.

Abstract: This invention provides novel arylindenopyridines of the formula: and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing Adensine A2a receptors or reducing PDE activity in appropriate cells. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.

Abstract: This invention provides novel arylindenopyridines of the formula: and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing Adensine A2a receptors or reducing PDE activity in appropriate cells. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.

Abstract: This invention provides novel arylindenopyridines of the formula: 1